Abstract |
The loss of early-phase insulin secretion is an important and early event in the natural history of type 2 diabetes. Because a normal pattern of insulin secretion is essential for the effective control of postprandial metabolism, a rational basis for the development of agents that target early-phase insulin release exists. Conventional oral hypoglycaemic agents do not target, or adequately control, postprandial glycaemia. The emergence of new classes of oral agent with a more specific mode of action provides, for the first time, an opportunity to restore early-phase insulin release. One such drug class is the meglitinide analogues ( repaglinide, nateglinide, and mitiglinide). These drugs are ideally suited for combination use with metformin. They could also prove effective in combination with a thiazolidinedione, a drug class that targets insulin resistance. Exogenous insulin is frequently required in the late management of type 2 diabetes. However, one hope for newer combinations of diabetic drugs is that the functional life of the beta cell can be extended, thereby delaying the need for insulin injections.
|
Authors | A Dornhorst |
Journal | Lancet (London, England)
(Lancet)
Vol. 358
Issue 9294
Pg. 1709-16
(Nov 17 2001)
ISSN: 0140-6736 [Print] England |
PMID | 11728565
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Benzamides
- Carbamates
- Cyclohexanes
- Hypoglycemic Agents
- Insulin
- Piperidines
- Nateglinide
- Phenylalanine
- repaglinide
- meglitinide
|
Topics |
- Adult
- Animals
- Benzamides
(therapeutic use)
- Carbamates
(pharmacokinetics, therapeutic use)
- Cyclohexanes
(pharmacokinetics, therapeutic use)
- Diabetes Mellitus, Type 2
(drug therapy, epidemiology, physiopathology)
- Humans
- Hypoglycemic Agents
(pharmacokinetics, therapeutic use)
- Insulin
(metabolism)
- Insulin Secretion
- Nateglinide
- Phenylalanine
(analogs & derivatives, pharmacokinetics, therapeutic use)
- Piperidines
(pharmacokinetics, therapeutic use)
- Rats
|